HYPE3

Hypera S.A., traded on B3 under the ticker HYPE3, is a publicly traded company headquartered in São Paulo whose trajectory began in 2001, when the then Monte Cristalina acquired Prátika Industrial, owner of the Assolan brand in the hygiene and cleaning segment. Over the 2000s, the company went through a period of diversification in consumer goods, operating in cosmetics, personal care products, food, cleaning products, disposables and condoms, through brands such as Monange, Risqué, Etti, Salsaretti, Assim, Pom Pom and Olla, among others. Starting in 2011, it began a portfolio rotation movement, gradually divesting from these businesses. Between 2011 and 2017, it sold food, cleaning, cosmetics, disposables and condom operations to groups such as Bunge, Flora, Química Amparo, Coty, Ontex and Reckitt Benckiser, progressively concentrating on the pharmaceutical market. In 2018, the change of corporate name to Hypera S.A. was accompanied by the adoption of the corporate brand “Hypera Pharma”, reflecting its exclusive focus on the healthcare sector. In 2023, the company was included in the B3 Corporate Sustainability Index (ISE) portfolio, reinforcing its visibility in the Brazilian capital markets.

The transformation of Hypera into an essentially pharmaceutical company was built through an extensive cycle of acquisitions and industrial reorganization. It entered the sector in 2007 with the acquisition of DM Indústria Farmacêutica, then the second-largest national player in over-the-counter (OTC) medicines and owner of brands such as Benegrip, Doril, Engov, Epocler, Biotônico Fontoura, Lacto-Purga and Merthiolate. In 2008, the purchase of Laboratório Americano de Farmacoterapia (Farmasa) consolidated its OTC leadership and marked its entry into prescription medicines, expanding its relationship with the medical community through brands such as PredSim, Milgamma and Lipanon. In 2009, the acquisition of Neo Química significantly expanded its presence in similar and generic medicines, making this brand one of the leaders in the segment in Brazil. Additional moves, such as the acquisition of Luper Indústria Farmacêutica in 2010 and Mantecorp in 2011, complemented the portfolio with new prescription, dermocosmetic and OTC brands, including Coristina D, Polaramine, Celestamine, Diprospan, Quadriderm and Episol.

Hypera’s current business model is structured around five major fronts: Prescription Products, Consumer Health, Similar and Generic Medicines, Skincare and Institutional Market. The Prescription Products unit covers prescription medicines (RX), dermocosmetics prescribed by physicians and OTX medicines which, although non-prescription, have their demand driven by promotion to the medical community. In this segment, the company operates in several therapeutic classes, such as analgesics, anti-inflammatories, antidiabetics, antihypertensives, antidepressants and vitamins, with brands such as Alivium, Lisador, Maxsulid, Nesina, Persur, Evortia, Milgamma, Rinosoro, Dramin and Addera D3. The Consumer Health unit concentrates OTC medicines and the sweetener portfolio, with highlights including Benegrip, Coristina D, Neosaldina, Doril, Engov, Estomazil, Gastrol, Polaramine, Lacto-Purga, Tamarine, Maracugina, Buscopan, Buscofem, Merthiolate, Biotônico Fontoura and Vitasay. In sweeteners, Hypera operates brands such as Zero-Cal, Finn and Adocyl, with broad presence in liquid and powdered formats.

The Similar and Generic Medicines unit, driven by the Neo Química brand, focuses on medicines that are interchangeable with reference drugs, sold at discounts relative to the official price list. The line of similar medicines includes brands such as Doralgina, Corticorten, Neosoro, Flavonid, Neolefrin, Neotoss, Neopiridin, Vitaminas Neo Química, Neocoflan, Massageol, Histamin, Hiscongex, Miorrelax and Torsilax. In generics, the portfolio covers a broad range of active ingredients, such as acyclovir, alprazolam, amoxicillin, atenolol, atorvastatin, azithromycin, bromopride, captopril, sildenafil citrate, ciprofloxacin, sertraline, trazodone, dipyrone, zolpidem, losartan, enalapril, naproxen, olanzapine, tadalafil and vildagliptin, among others. The strategy of this unit combines volume, breadth of molecules and a competitive pricing policy, supported by bioequivalence testing and regulatory requirements from the Brazilian health authority to ensure interchangeability with reference medicines.

In the Skincare segment, Hypera operates mainly through the Mantecorp Skincare brand, focused on dermocosmetics developed for Brazilian skin, with lines for sun protection, hydration, acne treatment, hyperpigmentation and specific care, such as Episol, Epidrat, Epidac, Pielus, Glycare, Blancy, Hidramamy and Lanidrat. Additionally, it operates the Simple Organic brand, focused on organic and vegan products, and Bioage, aimed at professional treatments in aesthetic clinics. These products are guided by dermatological input and undergo clinical studies to prove efficacy and safety. The Institutional Market, in turn, concentrates offerings for hospitals, clinics and the Public Health System, with a pipeline of new molecules and products, including initiatives in biologics such as Hyblut, in addition to medicines such as Pabexhy and Hyfol, seeking to expand the company’s presence in hospital-use treatments.

Hypera operates predominantly in the Brazilian pharmaceutical market, with commercial presence in 100% of the country’s states. Its industrial and logistics structure underwent consolidation between 2011 and 2014, with the transfer of its main pharmaceutical operations to Anápolis, in Goiás, one of the country’s main sector hubs. In this municipality, the company operates a distribution center with tens of thousands of storage positions, in facilities that meet Good Manufacturing Practices requirements and use integrated management systems (SAP). Pharmaceutical and dermocosmetic products are distributed mainly through the pharmacy channel, which includes large drugstore chains, specialized distributors and independent pharmacies. Sweeteners and some supplements are also sold through the food channel, covering supermarkets, hypermarkets, wholesalers and small retailers.

Hypera’s distribution chain combines direct sales to large retailers with an indirect channel based on distributors, which accounts for a relevant share of revenue from continuing operations. Transportation is mostly road-based and outsourced, using specialized carriers in line with the sanitary and regulatory requirements applicable to the pharmaceutical sector. The sales force is segmented by business unit and involves in-house sales representatives, promoters, demonstrators and third-party reps, focusing on in-store execution, shelf display, merchandising activities and trade marketing. In addition to interaction with retailers, the company maintains a structured relationship with the medical community, especially in the Prescription Products and Skincare units, which depend on professional recommendations.

From a regulatory standpoint, Hypera operates in a sector that is heavily supervised by health authorities, with strict requirements for registration, manufacturing, bioequivalence testing, pharmacovigilance and consumer communications. Generic and similar medicines must prove bioequivalence or bioavailability relative to reference products, while OTC medicines and dermocosmetics follow specific rules for advertising and labeling. The company also participates in biotechnology initiatives such as the Bionovis joint venture, focused on biotech products, aligning itself with the trend of expanding advanced therapies. In terms of environmental, social and governance practices, the inclusion of HYPE3 in B3’s Corporate Sustainability Index indicates the adoption of structured corporate governance, social and environmental responsibility and risk management policies, aspects that are increasingly monitored in the Brazilian stock market.

Sell-out figures by segment reinforce its profile as a diversified company within the pharmaceutical sector. In 2024, the Prescription Products, Consumer Health and Similar and Generic Medicines segments together accounted for most of the volume sold, while Skincare and Institutional Market represented smaller but growing shares. This portfolio mix, based on widely recognized brands, multiple therapeutic categories and complementary sales channels, positions Hypera as one of the leading pharmaceutical manufacturers listed on B3, focused on the medicines, dermocosmetics and health and wellness products markets in Brazil.